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ABSTRACT: 
Everyone experiences symptoms of anxiety during their lifetime. It is a normal 
physical or psychological response to stress, mediated through adrenaline 
(epinephrine) and noradrenaline (norepinephrine). Anxiety disorders are 
extreme or pervasive versions of this response, and include a spectrum of 
different conditions (NICE, 2019).   
In the UK, approximately 15-20% of the population experience an anxiety 
disorder at some stage in their life, and there is evidence that women are 
more prone to anxiety disorders than men (Bentall, 2016).  However, despite 
their prevalence anxiety disorders can be difficult to diagnose accurately as 
they are often co-morbid with each other, or with other mental illnesses.  They 
also frequently, present as physical illnesses.  They also frequently present as 
physical illnesses such as heart, or gastrointestinal conditions. 
Co-morbidity is often a feature of complex mental health presentations, and 
the author uses a case study to show how non-medical prescribing 
formulations, and basic pharmacology, relate to clinical practice.  
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The case study considers a complex presentation of anxiety, with associated 
depression and describes the stepped care approach to care and treatment 
advocated by the National Institute for Health and Clinical Excellence. 
Accurate medical/clinical diagnosis of a person’s specific anxiety disorder can 
help them understand their condition and ensure that they are offered the 
most appropriate treatment at the earliest opportunity.  The Diagnostic and 
Statistical Manual of Mental Disorders (American Psychiatric Association, 
2013) is the most widely accepted framework and nomenclature used by 
clinicians and researchers for the classification of mental disorders and is 
referred to in the case study. 
Mixed anxiety and depression is a common presentation in primary care 
characterised by a mix of anxiety and depressive symptoms without clear 
prominence of any one type and the presence of one or more physical 
symptoms, such as tremor, palpitations, lethargy etc, that are present for 
more than six months (Gask et al, 2018). 
Anxiolytic medication is often used as a first aid measure in anxiety and is 
very useful and appropriate for this.  It is, however, quite difficult to assess the 
longer-term effectiveness of these drugs as anxiety tends to vary for reasons 
other than drug treatment such as external pressures.  Long-term use of 
benzodiazepine drugs is generally not advised, for addiction/dependence 
reasons, and some people do get some withdrawal effects if they stop 
benzodiazepines suddenly, so when the time comes to stop, it is best to 
reduce the dose slowly.  
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There is good evidence (Hofmann, 2018 and NICE, 2019) to support the 
efficacy of psychological interventions in anxiety spectrum disorders.  
Consequently, self-help and CBT may be the first line of treatment for less 
severe cases and can be used in conjunction with medication.  General 
support and information about the condition, with an empathic understanding 
of the life circumstances that may be contributing to the anxiety can be 
helpful.   
INTRODUCTION 
People with anxiety can have a variety of symptoms (NICE, 2011).  These can 
be divided into two main groups, psychological and physical.  Psychological 
symptoms: include fear, irritability, poor concentration, restlessness, 
sensitivity to noise, disturbed sleep, such as waking during the night, 
unpleasant dreams etc and poor memory usually due to poor communication.  
Physical symptoms: are mainly due to increased muscle tension e.g. 
problems with passing wind, loose motions, blurred vision, dizziness, loss of 
libido, breathing problems such as tight chest, difficulty breathing, heart 
changes, such as palpitations, heart pain or missed beats, tension resulting in 
headache or tremor and panic attacks leading to sudden episodes of extreme 
anxiety or apprehension.  This is due to overactivity of many parts of the brain, 
usually caused by some external pressure or reason.  The symptoms may be 
caused by this overactivity.  The result is that many systems in the body 
become overactive e.g. muscle control, thinking, worrying etc (Tovote et al, 
2015). 
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The action of anxiolytic medications 
Although there are over 80 known different transmitters in the brain, each 
nerve ending only has one type.  These neurotransmitters tend to be grouped 
together and each seems to have specific roles.  In many mental health 
problems, it is known that some of these transmitters get out of balance e.g. if 
someone has an insufficient amount of a particular transmitter.  This can then 
cause symptoms. (Tovote et al, 2015 and Blows, 2016). 
Epinephrine (E) and norepinephrine (NE) are very similar neurotransmitters 
and hormones, and both play a role in the body's natural fight-or-flight 
response to stress.  Norepinephrine (NE), previously called noradrenaline 
(NA), in the body controls the heart and blood pressure.  In the brain it 
controls sleep, wakefulness, arousal, mood, emotion and drive 
(wakefulness/sleep wake behaviour).  Too much norepinephrine and 
someone may feel anxious and jittery etc.  Too little and they may feel 
depressed, sedated, dizzy, or have low blood pressure.  However, GABA is 
the key transmitter, in relation to anxiety as it is the brains natural calming 
agent.  It acts as a brake in the brain and keeps its activity in check.  When 
someone is overanxious, it may be that not enough GABA is being released in 
the brain to help calm it down.  Drugs such as the benzodiazepines, zopiclone 
and zolpidem increase the length of the action of the GABA.  This helps calm 
down the brain and reduces the number of  worrying  messages being passed.   
 
A benzodiazepine drug binds to the GABA and acts as an agonist for the 
inhibitory neurotransmitter to GABA.   It that sense it mitigates against the 
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sudden reduction in available GABA, which can trigger panic, restlessness, 
insomnia, and potentially convulsions or seizures.  
Benzodiazepines block GABA in its receptors, so the receptors are activated 
for longer, and so the brains natural calming messages are passed stronger 
(LeDoux, 2000 and 2015, and Blows, 2016).   
The important thing to remember is that anxiolytic medication mainly works by 
strengthening the brains natural calming agents, but they should not be 
considered just as tranquillisers although they may help someone to feel 
calmer, as they have a much more specific way of working, than simple 
sedation (LeDoux, 2015, and Blows, 2016). 
Why do people get side-effects? 
These drugs block GABA into its receptors, so the receptors are activated for 
longer, and so the brains natural calming messages are passed with more 
strength.  GABA is widespread throughout the brain, and so a few adverse 
side effects are due to this more generalised sedation, e.g. confusion etc.  
These should be able to be minimised by adjusting the dose.  Some 
benzodiazepines are also used for helping treat epilepsy, as calming drugs 
before operations, and as muscle relaxants (LeDoux, 2015, and Blows, 2016). 
CASE STUDY 
Sonia, a 37-year-old mortgage-broker, has an appointment at her local GP 
surgery, to see Derek (Advanced Nurse Practitioner) and arrives with Nathan 
her 7-year-old son who has been diagnosed with type 1 diabetes.  Sonia lives 
with her husband in her own 3-bedroom house. The woman appears 
tremulous and becomes tearful while talking about her son’s condition.  She 
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says that she has been very worried about her son and has not been sleeping 
very well for the past 5-6 months, though she has been eating reasonably well, 
although she admits that she has felt more tired and demotivated than usual.   
Sonia is still going to work but has found it hard to concentrate on her duties 
as well as before.  Because of this she constantly worries that she might 
make a serious mistake at work.  She says that she has managed to cope 
with the support of her husband.  However, he also works full-time and there 
have been days when she has found it difficult to get out of bed.  Currently 
Sonia feels that she is going through a bad patch and is hopeful that things 
will get better soon.  She does not see a problem with her self-esteem and 
finds her work enjoyable but exhausting. 
When asked, Sonia completely dismisses any idea of self-harm or suicide and 
says she would never even think about it.  She apologizes profusely to Derek 
for becoming emotional and asserts that she is normally very calm and 
composed but has become overwhelmed by the stress of her son’s illness.   
In relation to herself, she denies history of any mood episodes, either 
depression, or hypomania.  She drinks alcohol socially, never exceeding 8 
units per week.  She does not smoke or use any illicit drugs.  She describes 
herself as ‘driven’ and ‘ambitious’.  She is a keen runner and runs 14-18 miles 
a week. 
She agrees to a brief physical examination.  She has tachycardia of 108/min, 
her pulse is regular, and her blood pressure is 138/88 mmHg.  Her palms 
appear cold and sweaty but there is no other significant physical finding. 
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Sonia is pleasant, co-operative and Derek is able to quickly establish a good 
rapport with her.  She is clutching her son protectively but maintains good 
eye-to-eye contact throughout the interview.  Her speech is or a normal rate 
and volume.  Her mood is anxious and low.  She does not have any psychotic 
symptoms.  Sonia has a good insight into her symptoms.   
She does not have any ideas of self-harm, but Sonia reveals that two years 
ago, she ‘borrowed’ some anxiety and sleeping pills from her mother who kept 
a stock-pile of drugs for emergencies.  Sonia remembers the names Ativan 
and Zolpidem, from the drug boxes, but cannot recall the doses, and how 
regularly she took the pills.  
Sonia asks if she can be prescribed a benzodiazepine drug, and some  
sleeping tablets.  She says her husband thinks this would be a good idea.   
DISCUSSION 
There are many possible explanations as to why women such as Sonia 
develop anxiety disorders more frequently than men (Carver & Connor-Smith, 
2010).  Women are more likely to communicate their feelings and it is 
culturally more acceptable for women to feel anxiety.  This makes it easier for 
them to seek help, for the symptoms they might be experiencing.  It could also 
be due to men being more likely to self-medicate with substances such as 
alcohol in an effort to mask anxiety symptoms (Freeman and Freeman, 2013). 
Applying the Global Mental Health Assessment Tool (Sharma, 2004) Sonia is 
presenting with a mixture of anxiety and depression and depressive 
symptoms occurring in the context of her son’s illness.  She is feeling very 
stressed and increasingly reliant on her husband for support.   
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Medical/clinical diagnostic possibilities include:  
Mixed anxiety and depression:  This is a common presentation in primary care 
characterized by a mix of anxiety and depression symptoms without clear 
prominence of any one type and the presence of one or more physical 
symptoms typically tremor, palpitations, and lethargy present for more than 6 
months (NICE, 2009 and 2019). 
Depression: Sonia does have the core symptoms, namely low/anxious mood, 
reduced energy and some other symptoms  such as reduced concentration 
and poor sleep lasting more than two weeks suggesting a mild depressive 
episode. 
Bipolar disorder: needs to be excluded by asking about hypomanic/manic 
episodes (Paris, 2012).  Detailed history and mental state examination will be 
needed to establish the diagnosis and appropriate investigations to rule out 
any medical disorders will also be required. 
NICE guidelines (2009) suggest that when depressive and anxious symptoms 
coexist, the first priority should usually to be to treat the depression. 
Psychological treatment for depression often reduces anxiety, and many 
antidepressants also have sedative/anxiolytic effects.  The guidelines 
advocate a stepped care approach, which is a system of  delivering and 
monitoring treatments so that the most effective, but least resource-
intensive treatment is delivered first.  NICE support the use of Cognitive 
Behaviour Therapy (CBT), but not other psychodynamic psychotherapies 
(NICE, 2009).   
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The advice for mild depression does not help in uncertain decisions when a 
particular case may or may not benefit from medication, but this reflects the 
evidence available (Beck, 2009).  These milder presentations may be 
subthreshold disorders where health professionals allow the “medicalisation of 
unhappiness” (Burns, 2013).  In order to legitimise the engagement, when all 
that people may really need in these times of growing social isolation is some 
or more support (Carver & Connor-Smith, 2010). 
Sonia is ambitious, energetic, and committed to supporting her family, and 
succeeding in her career, but, in the short-term at least, she might benefit 
from some self-compassion.  Kindness and concern for self is recognised 
element of healing and mental health recovery (Lazarus, 2006).  Therefore, 
Sonia might be encouraged to attend a local peer-support group, and/or 
relaxation classes.  Social interventions like this should be viewed as 
‘protective’ factors that potentially might be helpful in mitigating risk and 
relieving some of the fear, distress and inertia associated with many 
presentations of anxiety and depression (Aspinwall & Taylor, 1997).  Also, it is 
possible that Sonia’s symptoms might dissipate, once she is assured that her 
son’s condition is manageable.  This might require some education about 
Type 1 diabetes, but potentially, it might benefit both Sonia and her child. 
A stepped care model approach (NICE, 2019) would be well suited to Sonia’s 
situation, as she has mild mood symptoms and as per the stepped care model, 
these are best treated initially, in a primary care setting (Tolin et al 2011).   
Watchful waiting, i.e.  a follow-up appointment within two weeks with 
reassurance is sensible as symptoms may resolve spontaneously but if 
Sonia’s symptoms persist on subsequent visits, brief psychological 
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interventions may be provided by either a primary care mental health 
practitioner or a practice counsellor.   
 
A stepped care model adapted from the National Institute for Health and 
Care Excellence guidelines for the management of depression 
 11 
Step 1 
Mild or suspected depression 
Assess, support, provide psycho-education, monitor and refer onwards as 
appropriate 
Step 2 
Mild to moderate depression 
Consider interventions to address psychosocial problems 
Psychological interventions (e.g. Cognitive behaviour therapy, self-help 
resources) 
Antidepressant according to the patient’s wishes and preferences 
Step 3 
No response or moderate to severe depression 
Medication 
High intensity psychological interventions 
Combined treatments and referral for specialist input as appropriate  
Step 4 
Severe and complex depression 




Motivational interviewing might also help Sonia change her behaviour (Miller 
& Rollnick, 2013).  Computerized cognitive behaviour therapy can also be 
helpful (Arnberg et al, 2014) and also healthy lifestyle advice about exercise 
and sleep hygiene.  Guided self-help using manuals or self-help books are 
other options available in primary care (Davidson et al, 2016). 
If Sonia’s symptoms worsen, treatment can be commenced taking into 
account her preferences.  Psychological treatments such as Cognitive 
Behaviour Therapy (CBT) or antidepressant/anxiolytic medication such as 
Selective Serotonin Reuptake Inhibitors (SSRIs) can be effectively 
administered in primary care  (Hofmann & Smits, 2008 and Hofmann, 2018). 
Treatment-resistive cases, psychotic symptoms, atypical symptoms or 
recurrent episodes should trigger a referral to specialist services.  At any 
stage, if risk profiles change rapidly and risk assessment indicates a risk to 
self, others or self-neglect a referral can be made to the crisis team for 
consideration of inpatient treatment (NICE, 2019). 
Given Sonia’s revelation about the lorazepam, it is necessary to gently remind 
her of the importance of only taking medication, that has been prescribed, and 
particularly the risks associated with long-term, unsupervised use of 
Medication and/or electroconvulsive therapy 
High-intensity psychological interventions 
Crisis service, combined treatments, multi-professional  and inpatient care 
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benzodiazepines, such as psychological addiction, dependence and 
withdrawal (Taylor et al, 2018).   
Her self-medication, with unprescribed drugs, could be interpreted as a form 
of safety behaviour.  In the context of clinical anxiety, safety behaviors are 
actions performed to prevent, escape, or minimize feared catastrophes and/or 
associated distress (Rachman et al, 2008).  Developing some “positive” safety 
behaviours, is something that needs to be discussed with Sonia, as part of her 
treatment/care plan, as these can reduce risks of relapse (Goetz, 2016), 
which for Sonia might be the temptation of taking unprescribed medication at 
some point in the future. 
Cases such as this one, where there is comorbidity, are associated with 
worse health outcomes (Miller et al, 2011), therefore, Derek, the Advanced 
Nurse Practitioner should speak to a GP urgently, to discuss an appropriate 
treatment plan for Sonia, and to confirm the diagnosis.  Effective inter-
disciplinary team working, is necessary to manage complex cases safely, and 
maximise wellbeing for service users and their families (Bailey, 2012).  In the 
circumstances, Derek is right to be cautious about prescribing a 
benzodiazepine drug. 
 
How should benzodiazepines be used? 
Benzodiazepines are used in the treatment and management of pathological 
and chronic anxiety, agitation and tension (NICE, 2019).  They act rapidly and 
are very useful first aid measures.  However, they will only form a small part of 
overall management, of such conditions and may help the person until other 
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anxiety management techniques, e.g. psychotherapy etc. can be carried out.   
NICE recommends (cited by Taylor et al, 2018) that “benzodiazepines should 
not be used to treat panic disorders” and “should only be used ‘with care’ in 
post-traumatic stress disorder”. 
Acute anxiety should not be assumed to be present for more than a month 
and benzodiazepines should not be lightly prescribed for longer than this, as 
benzodiazepines are known to enhance GABA transmission and also inhibit 
microsomal enzymes (Barlow, 2002 and Blows 2016).  
Some patients, especially those with chronic anxiety, have a tendency to self-
treat/medicate and benzodiazepines should be avoided in patients with a 
history of drug or alcohol abuse.  When benzodiazepines are used, those with 
a slower onset of action, such as GABA partial-agonist Clonazepam, may 
cause less dependence than Diazepam or Lorazepam (Taylor et al, 
2018).  Concern has been expressed that some anxiety drugs, such as 
Alprazolam (Xanax)  and Diazepam (Valium) have been used in many 




Side-effects of benzodiazepines 
Headaches, confusion, ataxia, dysarthria, blurred vision, gastrointestinal 
disturbances, jaundice, amnesia and paradoxical excitement are all possible 
adverse side effects of benzodiazepines, although drowsiness is the only 
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common side effect (Taylor et al, 2018).  Respiratory depression is rare with 
normal dose oral therapy but may be an added complication with sleep 
apnoea.  It must be looked out for when the IV route is used, especially with 
midazolam.  The IV injection can be painful and lead to thrombophlebitis due 
to the low water solubility of benzodiazepines (Taylor et al, 2018).  Diazepam 
is available in an emulsion form (Diazemuls) to overcome this problem.  
Benzodiazepines are poorly absorbed from the IM route and the rectal route 
(e.g. with diazepam rectal tubules) is an appropriate alternative (BNF, 2020).   
Comparative doses 
The dose(s) of each drug below is approximately equivalent to others.  Inter-
patient variability, different half-lives (a particular problem with the 
benzodiazepines) make exact calculations difficult. 
Table 1: Benzodiazepines/comparative doses (after BNF, 2020) 
Diazepam  5mg 
Chlordiazepoxide 15mg (10-15) 
Clobazam 10mg 
Flunitrazepam 0.5mg 
Flurazepam  7.5mg – 15mg 
Loprazolam 0.5mg – 1mg 
Lorazepam  0.5mg 
Lormetazepam 0.5-1mg 
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Oxazepam 15mg (15-40) 




Dependence is characterised by a strong need to continue taking a drug, a 
tendency to increase the dose, a psychological dependence on the effects of 
the drug and a characteristic abstinence syndrome.  All of these have been 
reported to occur with the benzodiazepines (Bandelow et al, 2015).  It has 
been pointed out that withdrawal symptoms are, in the milder states, very 








Table 2: Dependency/symptoms of withdrawal (after Taylor, et al 2018) 
Primary 
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Psychological  Tension, restlessness, agitation, panic 
attacks 
Physical Dry mouth, tremor, sweating, sleep 
disturbance, lethargy, headache, 
nausea 
Mental Impaired memory and concentration 
Secondary 
Moderate  Perceptual changes (hyper-sensitivity 
to light/sound) 
Dysphoria, flu like symptoms, anorexia, 
sore eyes. 
Depersonalisation, depression, 
abnormal sensations of movement. 





Management of benzodiazepine withdrawal 
Controlled withdrawal may take a long time with only small reductions in 
dosage every seven days or so being tolerated.  All symptoms tend to be 
worse with the shorter-acting or high potency drugs (particularly lorazepam) 
(Taylor, 2018). 
It is usual to transfer a patient onto a longer-acting drug e.g. Diazepam, and 
reduce the dose of that drug at a rate the patient finds acceptable (NICE, 
2019).  
 Many people find difficulty in completing these withdrawal programmes and 
long term support is essential.  The withdrawal syndrome has been reported 
to last for up to a year or longer (Rogers et al, 2007). 
 
 
Box 1:  Risk factors for poor withdrawal (after Taylor, et al 2018) 
 Previous severe withdrawal (including a history of seizures) or post-
withdrawal reaction 
 Lack of adequate social support 
 Elderly or infirm 
 History of inappropriate us of alcohol or other drugs of dependence 
 Concomitant severe medical biological or psychiatric illness 
(including personality problems) 
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Hypnotic drugs for sleep problems 
Such drugs may be useful in the short-term, but it is quite difficult to assess 
the longer-term effectiveness of these drugs as sleep tends to vary for 
reasons other than drug treatment e.g. external pressures etc (Klink, 1992).   
If it is decided that someone requires a hypnotic drug for a long time, rather 
than just when they need it, this should be discussed, by the clinical team 
(NICE, 2004).  Crucially, some people do get some withdrawal effects if they 
stop hypnotics suddenly e.g. rebound insomnia (Taylor et al, 2018).  When 
the time comes to stop, it is best to reduce the dose slowly. 
Other anxiolytic medication 
Buspirone is licensed for the short-term treatment of anxiety.  It does not act 
on benzodiazepine receptors but is thought to act at specific serotonin (5-HT) 
receptors (Taylor, 2018).  Response to treatment is slow, taking 4-6 weeks to 
reach maximum effect making it unsuitable for as required PRN use.   
However, the dependence and abuse liability of buspirone is low.  Beta-
blockers (e.g. propranolol) do not affect psychological symptoms, such as 
worry, tension and fear, but they can reduce the physical symptoms of anxiety 
such as heart palpitations and hand tremor (BNF, 2020).   Pregabalin is an 
anti-convulsant used for the treatment of certain types of epilepsy.  It is also 
licensed for the treatment of generalised anxiety disorder. (BNF, 2020). 
CONCLUSION 
We all experience symptoms of anxiety during our lifetime, and it is a “normal” 
physical and psychological response to stress, mediated through adrenaline 
(epinephrine), noradrenalin (norepinephrine), and GABA (LeDoux, 2001 and 
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2015).  As we have seen, anxiolytic medication blocks GABA into its receptors.  
GABA is widespread throughout the brain, and so a few side-effects are due 
to this more generalised sedation, especially with a hangover effect the next 
morning possible with some drugs e.g. nitrazepam. 
Anxiety disorders are extreme or pervasive versions of this response and 
include a spectrum of different conditions.  In the UK, approximately 15-20% 
of the population experience an anxiety disorder at some stage of their life 
(Bentall, 2016).  These can, however, be difficult to diagnose and treat 
accurately as they are often co-morbid with each other or with other mental 
illnesses.  They also frequently present as physical illnesses, such as heart or 
gastrointestinal conditions (Barlow, 2002). 
Key opportunities for Integrated Care Systems and mental health have been 
identified as: preventing ill health, linking physical and mental health and 
improving mental health services (Centre for Mental Health, 2020).  Without 
changes to prescribing practice, it is difficult to see how these ambitions, can 
be met.  This in term requires effective multi-disciplinary and interprofessional 
working, and person centred care. 
Prescribing medication for anxiety is fraught with difficulty and prescribers 
should endeavour to keep an open-mind, in relation to useful alternatives or 
adjuncts to drug therapy (Barker, 2011).  It is vital to fully explore the various 
treatment options, listening to the patient/client, acknowledging their 
preferences, and responding sensitively to any concerns they might have 
about drug side-effects (Moscarello & Hartley, 2017).  When it comes to 




Key Points (Box 2) 
 The symptoms of anxiety can be reduced by increasing the strength 
of the brains natural calming messages.   
 Anxiolytic medication helps by increasing the strength of the brains 
natural calming messages.   
 They are not ‘just tranquilisers’ although they may help someone 
feel calmer.   
 They do not directly alter personality.   
 Anxiolytics are not necessarily addictive, but it is best to stop them 
slowly if taken for more than about a month.   
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